Abivax releases the results of its may 30, 2024 ordinary and extraordinary general meeting

Paris, france, june 4, 2024 – abivax sa (euronext paris & nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on may 30, 2024 (the “general meeting”), which was chaired by mr. marc de garidel, ceo and chairman of the board of directors of abivax (“board”).
ABVX Ratings Summary
ABVX Quant Ranking